🇺🇸 FDA
Patent

US 11866503

Methods for treating inflammatory conditions of the airway or lungs by administering antagonist monoclonal antibodies to interleukin-33 and interleukin-4 receptor

granted A61KA61K2039/507A61K38/1793

Quick answer

US patent 11866503 (Methods for treating inflammatory conditions of the airway or lungs by administering antagonist monoclonal antibodies to interleukin-33 and interleukin-4 receptor) held by REGENERON PHARMACEUTICALS, INC. expires Mon Jan 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue Jan 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K2039/507, A61K38/1793, A61K39/3955, A61K45/06